Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)EBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares OutstandingShares Outstanding
Ratios

Phibro Animal Health (PAHC) EBIAT (2016 - 2026)

Phibro Animal Health has reported EBIAT over the past 14 years, most recently at $27.5 million for Q4 2025.

  • For Q4 2025, EBIAT rose 762.14% year-over-year to $27.5 million; the TTM value through Dec 2025 reached $92.1 million, up 376.73%, while the annual FY2025 figure was $48.3 million, 1897.68% up from the prior year.
  • EBIAT for Q4 2025 was $27.5 million at Phibro Animal Health, up from $26.5 million in the prior quarter.
  • Over five years, EBIAT peaked at $27.5 million in Q4 2025 and troughed at -$8.0 million in Q3 2023.
  • A 5-year average of $9.2 million and a median of $7.1 million in 2022 define the central range for EBIAT.
  • Biggest five-year swings in EBIAT: plummeted 307.86% in 2023 and later skyrocketed 2190.43% in 2025.
  • Year by year, EBIAT stood at $17.5 million in 2021, then tumbled by 58.72% to $7.2 million in 2022, then crashed by 82.33% to $1.3 million in 2023, then soared by 150.0% to $3.2 million in 2024, then surged by 762.14% to $27.5 million in 2025.
  • Business Quant data shows EBIAT for PAHC at $27.5 million in Q4 2025, $26.5 million in Q3 2025, and $17.2 million in Q2 2025.